Sort
15,842 grants matching “pancreatic cancer”
Controllable In Vivo Genome Editing for Immune-Checkpoint Blockade in Solid Tumors
$307,164Sheng Tong · University Of Kentucky · R01 · FY2019 · EB
Hedgehog Inhibitors in Pancreas Cancer
$307,115Anirban Maitra · Johns Hopkins University · R01 · FY2008 · CA
Hedgehog Inhibitors in Pancreas Cancer
$307,115Anirban Maitra · Johns Hopkins University · R01 · FY2009 · CA
Amplification of tumor hypoxic responses by MIF-dependent HIF stabilization
$307,100Robert A. Mitchell · University Of Louisville · R01 · FY2010 · CA
Amplification of tumor hypoxic responses by MIF-dependent HIF stabilization
$307,100Robert A. Mitchell · University Of Louisville · R01 · FY2009 · CA
Targeting Ras-Ral GEF-Ral Effector Signaling for Pancreatic Cancer Treatment
$307,100Jen Jen Yeh · Univ Of North Carolina Chapel Hill · R01 · FY2010 · CA
X-ray studies of metalloenzyme regulation and catalysis
$307,055Catherine L Drennan · Massachusetts Institute Of Technology · R01 · FY2006 · GM
Computational Models of the Human Cell Cycle to Reveal Disease Mechanism and Inform Treatment
$307,051Jeremy Purvis · Univ Of North Carolina Chapel Hill · R01 · FY2020 · GM
MicroRNA-1291 in Regulation of Xenobiotic Disposition and Cell Differentiation
$307,011Aiming Yu · University Of California At Davis · U01 · FY2014 · CA
PR55-alpha controlled PP2A in the regulation of the Hippo/YAP pathway
$307,000Ying Yan · University Of Nebraska Medical Center · R01 · FY2023 · GM
Mechanisms of TLR-mediated prevention of transplantation tolerance
$307,000Maria-Luisa Alegre · University Of Chicago · R01 · FY2008 · AI
PR55-alpha controlled PP2A in the regulation of the Hippo/YAP pathway
$307,000Ying Yan · University Of Nebraska Medical Center · R01 · FY2022 · GM
PR55-alpha controlled PP2A in the regulation of the Hippo/YAP pathway
$307,000Ying Yan · University Of Nebraska Medical Center · R01 · FY2024 · GM
A dietary intervention clinical trial to reduce inflammation and improve outcomes in chronic pancreatitis
$306,994Thomas A Mace · Ohio State University · R01 · FY2025 · DK
Mechanisms of immunomodulation with epigenetic therapy
$306,956Nilofer S. Azad · Johns Hopkins University · P01 · FY2023 · CA
Project 2: Biological Effects of Patient-derived Mutations in MUC16 on PC Metastasis
$306,946Michael A Hollingsworth · University Of Nebraska Medical Center · P01 · FY2019 · CA
Project 3: MUC16-Mediated Metabolic Reprograming Induces PC Metastasis
$306,945Pankaj Kumar Singh · University Of Nebraska Medical Center · P01 · FY2019 · CA
RON Receptor in Pancreatic Cancer Biology and Therapy
$306,943Andrew M Lowy · University Of California, San Diego · R01 · FY2021 · CA
RON Receptor in Pancreatic Cancer Biology and Therapy
$306,943Andrew M Lowy · University Of California, San Diego · R01 · FY2017 · CA
RON Receptor in Pancreatic Cancer Biology and Therapy
$306,943Andrew M Lowy · University Of California, San Diego · R01 · FY2020 · CA
RON Receptor in Pancreatic Cancer Biology and Therapy
$306,943Andrew M Lowy · University Of California, San Diego · R01 · FY2018 · CA
Molecular Markers for the Diagnosis of Pancreatic Cancer
$306,893Surinder Kumar Batra · University Of Nebraska Medical Center · R01 · FY2009 · CA
Molecular Markers for the Diagnosis of Pancreatic Cancer
$306,893Surinder Kumar Batra · University Of Nebraska Medical Center · R01 · FY2010 · CA
Hedgehog Inhibitors in Pancreas Cancer
$306,881Anirban Maitra · Johns Hopkins University · R01 · FY2007 · CA
Molecular Mechanisms of Adverse Metabolic Events by Asparaginase.
$306,856Tracy G. Anthony · Indiana University Indianapolis · R01 · FY2011 · HD